Arca
Skip to content

Psoriasis

Drug research and approvals for psoriasis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 16, 2026, 211 studies of psoriasis are recruiting on ClinicalTrials.gov, Health Canada has authorized 163 drug trials for it since 2013, FDA has 2 approved and 2 open orphan designations naming it, and the EU has 20 authorised medicines for it.

  • Recruiting worldwide: 211
  • Trials authorized in Canada: 163
  • FDA orphan approvals: 2
  • EU medicines: 20

Recruiting Now

Newest start dates first, of 211 recruiting on ClinicalTrials.gov ↗

Trials Authorized in Canada

The 10 newest of 163; search them all in Canada trials
Apr 8, 2026An open-label study with maintenance dosing to evaluate the long-term safety, tolerability, and efficacy of orka-002 in participants with moderate-to-severe…ORKA-002ORUKA THERAPEUTICS, INC.Ongoing
Feb 12, 2026An open-label extension study to evaluate the long-term safety, tolerability, and efficacy of orka-001 in participants with moderate-to-severe plaque psoriasisORKA-001ORUKA THERAPEUTICS, INC.Ongoing
Dec 16, 2025A multicenter, randomized, double-blinded, placebo-controlled dose-range finding study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of…ORKA-002ORUKA THERAPEUTICS, INC.Ongoing
Dec 11, 2025Multicenter, randomized, double-blinded, placebo controlled, dose-range finding study of orka-001 in participants with moderate-to-severe plaque psoriasisORKA-001ORUKA THERAPEUTICS, INC.Ongoing
Sep 19, 2025A phase 3b/4 multi-center, randomized, open-label, long-term safety study of deucravacitinib in comparison to ustekinumab in participants with…DEUCRAVACITINIB (BMS-986165)Bristol-Myers SquibbOngoing
Jul 16, 2025A multicenter, randomized, double-blinded, placebo -controlled study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of orka-001 in…ORKA-001ORUKA THERAPEUTICS, INC.Ongoing
Jun 23, 2025A multicenter, randomized, double-blind, placebo-controlled phase 3study to evaluate the efficacy, safety and pharmacokinetics ofdeucravacitinib in adolescent…DEUCRAVACITINIB (BMS-986165)Bristol-Myers SquibbOngoing
Jun 11, 2025A phase 3, randomized, multicenter, double-blind trial to evaluate the efficacy, safety, and tolerability of zasocitinib (tak-279) compared to deucravacitinib…ZASOCITINIB (TAK-279) / DEUCRAVACITINIBTakeda Pharmaceuticals USAClosed
Mar 28, 2025A phase 3 multicenter, randomized, double-blind, placebo-controlled and ustekinumab active comparator-controlled study to evaluate the efficacy and safety of…ICOTROKINRA (JNJ-77242113) / USTEKINUMABJohnson & JohnsonOngoing
Jan 17, 2025An extension study in patients with moderate to severe plaque psoriasis to evaluate the long-term safety, efficacy, and durability of response to esk-001…ENVUDEUCITINIB (ESK-001)ALUMIS INC.Ongoing

FDA Orphan Designations

Approved first, then open designations, newest first
Mar 18, 2024Spevigotreatment of generalized pustular psoriasis (GPP) in adults and pediatric patients 12 years of age and older and weighing at least 40 kgLEO Pharma Inc.Approved
Sep 1, 2022SpevigoTreatment of generalized pustular psoriasis (GPP) flares in adultsLEO Pharma Inc.Approved
Oct 16, 2023Recombinant Humanized Anti-interleukin 36R Monoclonal…Treatment of generalized pustular psoriasisShanghai Huaota Biopharmaceutical Co., Ltd.Designated
Jul 7, 2020imsidolimabTreatment of generalized pustular psoriasisVanda Pharmaceuticals Inc.Designated

Medicines Authorised in the EU

Newest first; 15 of 20
Sep 18, 2026Icotydeicotrokinra hydrochlorideJanssen-Cilag InternationalEMA ↗
Sep 17, 2025Usrentyustekinumab · biosimilarBiosimilar Collaborations Ireland LimitedEMA ↗
Aug 14, 2025Usymroustekinumab · biosimilarGedeon Richter Plc.EMA ↗
Feb 14, 2025Yesintekustekinumab · biosimilarBiosimilar Collaborations Ireland LimitedEMA ↗
Sep 25, 2024Otulfiustekinumab · biosimilarFresenius Kabi Deutschland GmbHEMA ↗
Aug 22, 2024Steqeymaustekinumab · biosimilarCelltrion Healthcare Hungary Kft.EMA ↗
Jun 20, 2024Wezenlaustekinumab · biosimilarAmgen Technology (Ireland) UCEMA ↗
Jan 5, 2024Uzpruvoustekinumab · biosimilarStada Arzneimittel AGEMA ↗
Mar 24, 2023SotyktudeucravacitinibBristol-Myers Squibb Pharma EEIGEMA ↗
Dec 9, 2022SpevigospesolimabLEO Pharma A/SEMA ↗
Aug 20, 2021BimzelxbimekizumabUCB Pharma S.A.EMA ↗
Apr 26, 2019SkyrizirisankizumabAbbVie Deutschland GmbH & Co. KGEMA ↗
Sep 17, 2018IlumetritildrakizumabAlmirall, S.A.EMA ↗
May 18, 2018Zesslyinfliximab · biosimilarSandoz GmbHEMA ↗
Nov 10, 2017TremfyaguselkumabJanssen-Cilag International NVEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.